Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

SIGLEC Phase 2b data support AVD-104 as a potential therapy to reduce GA lesion growth, preserve and improve visual acuity, and reduce conversion to neovascular AMD across all GA lesion types at 1 ...

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Dimerix completes patient enrolment in ACTION3 phase 3 trial of DMX-200 to treat focal segmental glomerulosclerosis: Melbourne, Australia Tuesday, December 16, 2025, 18:00 Hrs [IS ...

Since acquiring exclusive rights to launch and commercialise catumaxomab in 2024, in partnership with Lindis Biotech, Pharmanovia has been committed to ensuring people have access to a treatment that ...

Precision immunotherapy targeting immune dysregulation improves organ dysfunction in sepsis patients. Learn more about this ...

Collagenase-like protease (Clp) enhances the toxic effect of Streptococcus suis serotype 2 (SS2). Clp increases the permeability of the blood–brain barrier by disrupting tight junctions and inducing ...